Scalper1 News
Big-cap biotech Gilead Sciences beat analysts’ fourth-quarter estimates on both the top and bottom lines late Tuesday and offered 2014 sales guidance for the first time, but didn’t project sales for its newly launched, much anticipated drug Sovaldi. After the markets closed, Gilead Sciences (GILD) said profit in the quarter rose 10% over the year-earlier quarter to 55 cents a share, beating analysts’ consensus by 5 cents, according to Thomson Scalper1 News
Scalper1 News